Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Tallal Younis; Chris Skedgel

doi:10.2165/11588350-000000000-00000

Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial

Tallal Younis, Chris Skedgel

Engineering

科研成果: 期刊稿件 › 评论/辩论 › 同行评审

2 引用（Scopus）

源语言	英语
页（从-至）	361-365
页数	5
期刊	PharmacoEconomics
卷	29
期	5
DOI	https://doi.org/10.2165/11588350-000000000-00000
出版状态	已出版 - 2011

!!!ASJC Scopus Subject Areas

药理学
卫生政策
公共卫生、环境和职业健康

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

访问文件

10.2165/11588350-000000000-00000

其它文件与链接

引用此

@article{600da06108104a7a9602e1573647c2fb,

title = "Adjuvant trastuzumab for breast cancer: Uncertainties in clinical and economic evidence following early stopping of the HERA trial",

author = "Tallal Younis and Chris Skedgel",

year = "2011",

doi = "10.2165/11588350-000000000-00000",

language = "English",

volume = "29",

pages = "361--365",

journal = "PharmacoEconomics",

issn = "1170-7690",

publisher = "Adis International Ltd",

number = "5",

}

TY - JOUR

T1 - Adjuvant trastuzumab for breast cancer

T2 - Uncertainties in clinical and economic evidence following early stopping of the HERA trial

AU - Younis, Tallal

AU - Skedgel, Chris

PY - 2011

Y1 - 2011

UR - http://www.scopus.com/inward/record.url?scp=79955052041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955052041&partnerID=8YFLogxK

U2 - 10.2165/11588350-000000000-00000

DO - 10.2165/11588350-000000000-00000

M3 - Comment/debate

C2 - 21504237

AN - SCOPUS:79955052041

SN - 1170-7690

VL - 29

SP - 361

EP - 365

JO - PharmacoEconomics

JF - PharmacoEconomics

IS - 5

ER -